Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | GRM8 | O00222 | 2/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495462 | 0.88 | KDM4E (0.38) | POLBKDM4ECYP1A2GRM8GRM7 | |
| SCHEMBL2933140 | 0.87 | CRHR1 (0.38) | POLBKDM4ECYP1A2GRM8GRM7 | |
| SCHEMBL2931270 | 0.87 | HPGD (0.39) | POLBKDM4EHTTMAPTHPGD | |
| SCHEMBL2497805 | 0.85 | HPGD (0.38) | POLBKDM4EHTTMAPTHPGD | |
| SCHEMBL2495432 | 0.85 | POLB (0.40) | POLBKDM4ECYP1A2GRM8GRM7 | |
| SCHEMBL2493432 | 0.84 | CYP1A2 (0.37) | POLBKDM4ECYP1A2GRM8GRM7 | |
| SCHEMBL2931328 | 0.83 | PIK3CG (0.38) | POLBKDM4ECYP1A2GRM8GRM7 | |
| SCHEMBL2932900 | 0.82 | CRHR1 (0.47) | POLBKDM4EHPGDLMNAMEN1 | |
| SCHEMBL545543 | 0.80 | HPGD (0.40) | POLBKDM4EHTTMAPTHPGD | |
| SCHEMBL2929947 | 0.80 | CYP1A2 (0.34) | POLBKDM4ECYP1A2GRM8GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030304-B2 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2094709-B1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | CRHR1, CRH, CRHR2 | POLB 4776/4885KDM4E 4562/4885CYP1A2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.